Department of Cardiovascular Diseases, Mayo Clinic, 200 First Street, SW, Rochester, MN, USA.
Department of Biomedical Statistics, Mayo Clinic, Rochester, MN, 55905, USA.
ESC Heart Fail. 2023 Apr;10(2):1270-1279. doi: 10.1002/ehf2.14309. Epub 2023 Jan 30.
To identify different red blood cell mass (RBCM) profiles, separate from haemoglobin concentrations, and their impact on blood volume expansion and clinical outcomes in chronic heart failure.
RBCM was measured at hospital discharge using standardized nuclear medicine indicator-dilution methodology in patients following diuretic treatment for clinical congestion. Individual RBCM phenotypes were prospectively identified and analysed for heart failure-related mortality or first rehospitalization over 1 year. Of 132 patients, 42 (32%) demonstrated normal RBCM, 36 (27%) RBCM deficit (true anaemia), and 54 (41%) RBCM excess (erythrocythemia). Dilutional 'anaemia' defined by haemoglobin <12 g/dL with normal or an excess in RBCM with plasma volume expansion was identified in 37 (28%) patients. There were 61 composite outcome events, which included 38 deaths (29% of cohort) occurring over the 1 year follow-up period [14/36 (39%) in RBCM deficit, 12/42 (29%) in normal RBCM, and 12/54 (22%) in RBCM excess subgroups]. By Kaplan-Meier and multivariate analyses, RBCM excess was independently associated with the best event-free survival while RBCM deficit (true anaemia) the poorest outcomes; both compared with normal RBCM (P < 0.001). Dilutional 'anaemia' demonstrated a lower risk compared with true anaemia (P = 0.03).
Markedly different RBCM profiles are identifiable among comparably compensated heart failure patients, and this variability carries significant implications for post-hospital outcomes. Novel to this analysis and in contrast to RBCM deficit is the independent association of RBCM excess with better event-free survival compared with normal RBCM. The distinction of RBCM profiles to guide risk stratification and individualized patient management strategies warrants further study.
确定与血红蛋白浓度分开的不同红细胞量(RBCM)谱,并研究其对慢性心力衰竭患者血容量扩张和临床结局的影响。
对接受利尿剂治疗以缓解临床充血的患者,在出院时使用标准化核医学指示剂稀释法测量 RBCM。前瞻性地识别个体 RBCM 表型,并分析其 1 年内与心力衰竭相关的死亡率或首次再入院。在 132 例患者中,42 例(32%)表现为正常 RBCM,36 例(27%)为 RBCM 不足(真性贫血),54 例(41%)为 RBCM 过多(红细胞增多症)。血红蛋白 <12 g/dL 且 RBCM 正常或过多伴血浆容量扩张定义的稀释性“贫血”,在 37 例(28%)患者中被识别出来。共有 61 例复合终点事件,其中包括 38 例死亡(队列的 29%),发生在 1 年的随访期间[RBCM 不足组 14/36(39%),正常 RBCM 组 12/42(29%),RBCM 过多组 12/54(22%)]。通过 Kaplan-Meier 和多变量分析,RBCM 过多与最佳无事件生存独立相关,而 RBCM 不足(真性贫血)则与最差结局相关;与正常 RBCM 相比,这两种情况的差异均有统计学意义(P<0.001)。与真性贫血相比,稀释性“贫血”的风险较低(P=0.03)。
在代偿性心力衰竭患者中可识别出明显不同的 RBCM 谱,这种变异性对住院后结局有重要影响。与 RBCM 不足不同,RBCM 过多与正常 RBCM 相比,与更好的无事件生存独立相关,这是本分析的新发现。区分 RBCM 谱以指导风险分层和个体化患者管理策略,值得进一步研究。